Mars Bioimaging

We are able to transition seamlessly between translation studies spanning from imaging phantoms to in vivo murine models. We are glad to have the latest spectral (multi-energy) CT system which enables non-invasive imaging and quantification of various components simultaneously in small animals. We are fortunate to have the MARS scanner at HKU Department of Diagnostic Radiology with it state-of-the-art photon-counting detectors and multi-spectral energy capability. MARS Bioimaging Ltd (MBI) was founded in 2007 to commercialize the cutting-edge Medipix technology and bring photon-counting CT to the clinic. MBI has established itself as the world’s leading research and development group in spectral molecular imaging, and to-date has delivered the world’s first commercial pre-clinical spectral CT scanner. MBI works closely with customers to provide a wide range of spectral imaging solutions for applications ranging from cancer detection to development of novel contrast agents. Mark Figgitt is a highly respected executive and director with four decades of technology and leadership experience, including leading growth for health software, cardiology and radiology providers, Change Healthcare ANZ and HSTM Group NZ for the past six years. Professor Anthony Butler is a clinical radiologist with an interest in developing new imaging technologies.